Abstract
Long acting (or extended release) injectable buprenorphine formulations for the treatment of opioid dependence have been introduced in a number of countries in recent years. One such product, Buvidal, available as Weekly or Monthly subcutaneous injections, has been increasingly used in many European countries and Australia for several years, and has recently been registered under the brand name Brixadi in the United States. This review provides an overview of opioid dependence, examines the rationale for the development of Buvidal, its pharmacological properties, evidence of efficacy and safety, and key principles of clinical care in the treatment of opioid dependence. Particular attention is given to issues of pain management, pregnancy, and treatment in custodial settings. This long-acting injectable buprenorphine product is an important addition to the available options for the treatment of opioid dependence, providing a safe and effective alternative to treatment with medications requiring daily dosing.